Scott A Tomlins
Adjunct Associate Professor of Pathology
Adjunct Associate Professor of Urology
[email protected]

Available to mentor
Scott A Tomlins
Adjunct Associate Professor
  • Center Memberships
  • Recent Publications
    • Center Memberships
    • Center Member
      Taubman Institute
    • Center Member
      Center for Computational Medicine and Bioinformatics
    • Center Member
      Rogel Cancer Center
    Recent Publications See All Publications
    • Journal Article
      Integrative multi-region molecular profiling of primary prostate cancer in men with synchronous lymph node metastasis.
      Singhal U, Nallandhighal S, Tosoian JJ, Hu K, Pham TM, Stangl-Kremser J, Liu C-J, Karim R, Plouffe KR, Morgan TM, Cieslik M, Lucianò R, Shariat SF, Finocchio N, Dambrosio L, Doglioni C, Chinnaiyan AM, Tomlins SA, Briganti A, Palapattu GS, Udager AM, Salami SS. Nat Commun, 2024 May 21; 15 (1): 4341 DOI:10.1038/s41467-024-48629-y
      PMID: 38773085
    • Journal Article
      PP01.106 Validation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab Monotherapy Benefit in First Line (1L) Non-small cell lung cancer (NSCLC)
      Oakley B, Moon J, Connolly M, Burkard ME, Suga JM, Thomas S, Bulen BJ, Lamb LE, Khazanov NA, Hovelson D, Vakil H, Dusenbery A, Mowers J, Kwiatkowski K, Johnson DB, Rhodes DR, Tomlins SA, Safa M. Journal of Thoracic Oncology, 2024 Jul; 19 (7): e47 DOI:10.1016/j.jtho.2024.05.333
    • Journal Article
      Evaluation of a predictive biomarker for antibody drug conjugates (ADCs).
      Thomas SP, Habel LA, Suga JM, Achacoso N, Nugent J, Robinson KM, White R, Inman J, Plouffe K, Kwiatkowski K, Johnson B, Rhodes DR, Tomlins SA. Journal of Clinical Oncology, 2024 Jun 1; 42 (16_suppl): 3140 - 3140. DOI:10.1200/jco.2024.42.16_suppl.3140
    • Journal Article
      Abstract PO1-14-04: A multivariate biomarker to guide antibody-drug conjugate selection and provide insight on response differences across breast cancer subtypes
      Lamb L, Mowers J, Nasrazadani A, Burkard M, Khazanov N, Hovelson D, Kwiatkowski K, Tomlins S, Johnson DB, Rhodes D. Cancer Research, 2024 May 2; 84 (9_Supplement): po1-14-04-po1-14-04 DOI:10.1158/1538-7445.sabcs23-po1-14-04
    • Journal Article
      Abstract 5101: Comparative genomic analysis reveals distinctive immune profiles in MET exon 14 mutated and MET amplified lung cancer
      Javeri S, Minne R, Ramesh S, Baschnagel A, Kimple R, Lamb L, Tomlins S, Johnson B, Khazanov N. Cancer Research, 2024 Mar 22; 84 (6_Supplement): 5101 - 5101. DOI:10.1158/1538-7445.am2024-5101
    • Journal Article
      Development and application of a precision cell-free DNA (cfDNA) minimal residual disease (MRD) test to enable optimized treatment selection in patients with genitourinary (GU) cancers.
      Cooley D, Vaishampayan UN, Kaffenberger S, Drnek L, Johnson B, Lamb LE, Khazanov NA, Hovelson DH, Kwiatkowski K, Rhodes DR, Tomlins SA, Hafez K, Herrel LA, Montgomery JS, Gursky A, Udager AM, Morgan TM. Journal of Clinical Oncology, 2024 Feb 1; 42 (4_suppl): 473 - 473. DOI:10.1200/jco.2024.42.4_suppl.473
    • Journal Article
      Development and validation of a tumor tissue based multivariate biomarker for predicting angiogenesis inhibitor clinical benefit in renal cell carcinoma (RCC).
      Thomas SP, Vaishampayan UN, Johnson B, Lamb LE, Mowers J, Bulen BJ, Khazanov NA, Hovelson DH, Kwiatkowski K, Rhodes DR, Tomlins SA. Journal of Clinical Oncology, 2024 Feb 1; 42 (4_suppl): 467 - 467. DOI:10.1200/jco.2024.42.4_suppl.467
    • Journal Article
      Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer.
      Tosoian JJ, Zhang Y, Xiao L, Xie C, Samora NL, Niknafs YS, Chopra Z, Siddiqui J, Zheng H, Herron G, Vaishampayan N, Robinson HS, Arivoli K, Trock BJ, Ross AE, Morgan TM, Palapattu GS, Salami SS, Kunju LP, Tomlins SA, Sokoll LJ, Chan DW, Srivastava S, Feng Z, Sanda MG, Zheng Y, Wei JT, Chinnaiyan AM, EDRN-PCA3 Study Group . JAMA Oncol, 2024 Jun 1; 10 (6): 726 - 736. DOI:10.1001/jamaoncol.2024.0455
      PMID: 38635241